CCCristina Serrano-Del Castillo

Cristina Serrano-Del Castillo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristina Serrano-Del Castillo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman—Report of a Case with 9-Year Survival

    by Carlos Santonja, Daniel Morillo-Giles, Elena Prieto-Pareja, Carlos Soto-De Ozaeta, Cristina Serrano-Del Castillo, Rocío Salgado-Sánchez, Ana-Wu-Yang Yi-Shi, Rebeca Manso, Socorro María Rodríguez-Pinilla

    Anaplastic large cell lymphoma (ALCL) with leukaemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK expression in the neoplastic cells, it features a dismal prognosis. We report a rare case of leukaemic, small cell variant ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukaemic variant of ALK-positive ALCL.


  • Open Access

    LEUKAEMIC PRESENTATION OF SMALL-CELL ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN A YOUNG WOMAN. REPORT OF A CASE WITH 9-YEAR SURVIVAL.

    by Carlos Santonja, Daniel Morillo-Giles, Elena Prieto-Pareja, Carlos Soto-De Ozaeta, Cristina Serrano-Del Castillo, Rocío Nieves Salgado, Ana-Wu-Yang Yi-Shi, Rebeca Manso, Maria Rodriguez-Pinilla

    Anaplastic large cell lymphoma (ALCL) with leukemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK-status in the neoplastic cells, it features a dismal prognosis. We report a case of leukemic, ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukemic variant of ALCL.

  • Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis

    by D. Subirá, M. Simó, J. Illán, C. Serrano, S. Castañón, R. Gonzalo, J. J. Granizo, M. Martínez-García, M. Navarro, J. Pardo, et al.

    Some patients with epithelial-cell cancers develop leptomeningeal carcinomatosis (LC), a severe complication difficult to diagnose and with an adverse prognosis. This study explores the contribution of flow cytometry immunophenotyping (FCI) to the diagnosis and prognosis of LC. Cerebrospinal fluid (CSF) samples from patients diagnosed with LC were studied using FCI. Expression of the epithelial-cell adhesion molecule (EpCAM) was the criterion used to identify the epithelial cells. To test the diagnostic precision, 144 patients (94 diagnosed with LC) were included. The prognostic value of FCI was evaluated in 72 patients diagnosed with LC and eligible for therapy. Compared with cytology, FCI showed greater sensitivity and negative predictive value (79.79 vs. 50 %; 68.85 vs. 51.55 %, respectively), but lower specificity and positive predictive value (84 vs. 100 %; 90.36 vs. 100 %, respectively). The multivariate analysis revealed that the percentage of CSF EpCAM+ cells predicted an increased risk of death (HR: 1.012, 95 % CI 1.000–1.023; p = 0.041). A cut-off value of 8 % EpCAM+ cells in the CSF distinguished two groups of patients with statistically significant differences in overall survival (OS) (p = 0.018). This cut-off value kept its statistical significance regardless of the absolute CSF cell-count. The FCI study of the CSF improved the sensitivity for diagnosing LC, but refinement of the technique is needed to improve specificity. Furthermore, quantification of CSF EpCAM+ cells was revealed to be an independent prognostic factor for OS in patients with LC eligible for therapy. An 8 % cut-off value contributed to predicting clinical evolution before initiation of therapy.